apo-rivaroxaban tablet
apotex inc - rivaroxaban - tablet - 10mg - rivaroxaban 10mg
reddy-rivaroxaban tablet
dr reddy's laboratories ltd - rivaroxaban - tablet - 10mg - rivaroxaban 10mg
taro-rivaroxaban tablet
taro pharmaceuticals inc - rivaroxaban - tablet - 10mg - rivaroxaban 10mg
pms-rivaroxaban tablet
pharmascience inc - rivaroxaban - tablet - 10mg - rivaroxaban 10mg
pro-rivaroxaban tablet
pro doc limitee - rivaroxaban - tablet - 10mg - rivaroxaban 10mg
pmsc-rivaroxaban tablet
pharmascience inc - rivaroxaban - tablet - 10mg - rivaroxaban 10mg - direct factor xa inhibitors
teva-rivaroxaban tablet
teva canada limited - rivaroxaban - tablet - 10mg - rivaroxaban 10mg
apo-rivaroxaban rivaroxaban 10 mg tablet blister pack
arrotex pharmaceuticals pty ltd - rivaroxaban, quantity: 10 mg - tablet - excipient ingredients: silicon dioxide; polyvinyl alcohol; lactose; iron oxide red; titanium dioxide; croscarmellose sodium; poloxamer; purified talc; magnesium stearate; macrogol 8000 - rivaroxaban is indicated for the prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks)
apo-rivaroxaban rivaroxaban 10 mg tablet bottle
arrotex pharmaceuticals pty ltd - rivaroxaban, quantity: 10 mg - tablet - excipient ingredients: iron oxide red; titanium dioxide; silicon dioxide; lactose; polyvinyl alcohol; purified talc; magnesium stearate; poloxamer; macrogol 8000; croscarmellose sodium - rivaroxaban is indicated for the prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks)
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotic agents - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.-------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.